title: Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
abstract: Doxorubicin-loaded long-circulating liposomes (Doxil, ALZA Corp.) were additionally modified with the nucleosome-specific monoclonal antibody 2C5 (mAb 2C5) recognizing a broad variety of tumor cells via the tumor cell surface-bound nucleosomes. These mAb 2C5-modified PEGylated liposomes demonstrated 3-8-fold increase in the in vitro binding and internalization by multiple cancer cell lines of diverse origins (murine LLC, 4T1, C26 and human BT-20, MCF-7, and PC3), as shown by flow cytometry (FACS) and epi and confocal microscopy. As a result, mAb 2C5-modified Doxil demonstrated significantly higher cytotoxicity towards various cancer cells, including those resistant to doxorubicin, than all control preparations. The specific internalization of the mAb 2C5-Doxil into cytosol, along with the nuclear localization of their drug load, inside the target cancer cells were mainly responsible the superior anticancer activity. The IC50 values of mAb 2C5-Doxil with various murine and human cancer cells were 5-8-fold lower than those of control doxorubicin-loaded liposomes, Doxil or Doxil modified with a nonspecific IgG.
authors: Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA.
authors: Tamer A
authors: TA
authors: Elbayoumi
authors: Vladimir P
authors: VP
authors: Torchilin
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000378:metabolism*; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000378:metabolism / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004339:Drug Compounding; D004705:Endocytosis; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D008081:Liposomes; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009707:Nucleosomes / Q000276:immunology; D011092:Polyethylene Glycols / Q000737:chemistry*; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D008081:Liposomes; D009707:Nucleosomes; D011092:Polyethylene Glycols; D004317:Doxorubicin
references: Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90
references: 15717738
references: Clin Cancer Res. 2005 May 1;11(9):3567-73
references: 15867261
references: Pharm Res. 2005 Jun;22(6):933-9
references: 15948037
references: Cancer Res. 2001 Mar 15;61(6):2592-601
references: 11289136
references: Cancer Res. 1992 Dec 15;52(24):6774-81
references: 1458465
references: Cancer Invest. 2004;22(5):663-9
references: 15581046
references: Biochim Biophys Acta. 2001 Apr 2;1511(2):397-411
references: 11286983
references: Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205
references: 16763815
references: J Clin Pharmacol. 1996 Jan;36(1):55-63
references: 8932544
references: J Pharm Sci. 2005 Aug;94(8):1782-93
references: 15986461
references: Expert Rev Anticancer Ther. 2002 Apr;2(2):143-50
references: 12113236
references: Curr Drug Deliv. 2005 Oct;2(4):369-81
references: 16305440
references: J Control Release. 2003 Aug 28;91(1-2):115-22
references: 12932643
references: J Control Release. 2004 Nov 5;100(1):135-44
references: 15491817
references: Clin Cancer Res. 2000 May;6(5):1949-57
references: 10815920
references: J Control Release. 2001 Jul 6;74(1-3):95-113
references: 11489487
references: Cancer Detect Prev. 1998;22(5):470-5
references: 9727629
references: Adv Drug Deliv Rev. 1998 Feb 2;29(3):249-271
references: 10837594
references: Biochim Biophys Acta. 2001 Oct 1;1514(2):303-17
references: 11557029
references: Drug Resist Updat. 2003 Oct;6(5):271-9
references: 14643297
references: Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91
references: 11438707
references: Life Sci. 2000 Dec 8;68(3):273-81
references: 11191643
references: Crit Rev Ther Drug Carrier Syst. 1998;15(6):587-627
references: 9883391
references: Oncol Res. 1997;9(8):439-46
references: 9436197
references: Ann Oncol. 2000 Aug;11(8):1029-33
references: 11038041
references: Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
references: 1763060
references: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references: 15688077
references: Cancer Res. 2003 Jan 1;63(1):86-92
references: 12517782
references: Proc Natl Acad Sci U S A. 2003 May 13;100(10):6039-44
references: 12716967
references: Clin Oncol (R Coll Radiol). 1994;6(5):294-6
references: 7530036
references: Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91
references: 11033430
references: Immunol Lett. 1995 Jul-Aug;47(1-2):147-9
references: 8537094
references: Cancer Res. 1994 Apr 15;54(8):2186-91
references: 8174126
references: J Drug Target. 2005 Jul;13(6):337-43
references: 16278153
references: Semin Oncol. 2000 Dec;27(6 Suppl 11):53-63; discussion 92-100
references: 11236029
references: J Drug Target. 2002 Nov;10(7):535-8
references: 12683720
references: Biochim Biophys Acta. 1995 Feb 15;1233(2):134-44
references: 7865538
references: Cancer Res. 1992 Feb 15;52(4):891-6
references: 1737351
references: Cancer Res. 2002 Dec 15;62(24):7190-4
references: 12499256